Melior Enters Research Collaboration With Pfizer
EXTON, Pa., April 09, 2007 /PRNewswire-FirstCall/ -- Melior Discovery, Inc. announced today that it has signed an agreement with Pfizer, Inc., under which Melior's in vivo theraTRACE indications discovery platform will be used to evaluate the activity of selected Pfizer compounds.
"Our agreement represents a significant opportunity for Melior to deliver value to Pfizer through the application of our unique and innovative in vivo testing platform," said Andrew Reaume, PhD, President and CEO of Melior. "We look forward to a productive collaboration."
Melior Discovery is leading the transformation of pharmaceutical drug repositioning with its unique theraTRACE platform of multiplexed in vivo models. It is using this capability to both build an internal pipeline of development candidates as well as sharing this capability with pharma and biotechnology company partners. In the former case, Melior is identifying "privileged" compounds that have been discontinued by others which it identifies through a close working relationship with Dr. Christopher Lipinski. In its partnered arrangements, Melior offers pharmaceutical partners an approach to expand their late-stage pipelines with safe, high-quality drug candidates.
CONTACT: Andrew Reaume, President & CEO of Melior Discovery,+1-610-280-0633, firstname.lastname@example.org
Web site: http://www.meliordiscovery.com/
Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company
Posted: April 2007